Broad application across solid tumors independent of tumor type, biomarker and mutational status.
Cancer therapies work best when the tumor contains high numbers of primed immune cells, namely T cells.
Transplant rejection immune response is 1000x stronger than response to flu or COVID. Largest T cell pool.
Maximize efficacy of checkpoint immunotherapy, T cell engagers, TIL, CAR-T. Localized delivery during biopsy or surgery.
Improve outcomes for patients with advanced solid tumors and limited therapeutic options. A minority of patients have had remarkable responses, however the majority do not experience clinically meaningful responses.
Tumors hide from the immune system and exclude immune cells. Only immune cell rich tumors respond to checkpoint immunotherapy. AIM-001 induces immune cells to flood the tumor.
AIM-001 is an intratumoral therapy that converts “cold” tumors “hot” by activating and recruiting the largest T cell pool in human biology to the tumor to increase durable response rates and patient eligibility.
Clinically safe and active TLR agonism + genetically mismatched adipocytes trigger an influx of activated immune cells to convert checkpoint refractory into checkpoint responsive disease.
